FFA
RIGL icon

Frazier Financial Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Frazier Financial Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18
Closed -$487 – 802
2026
Q1 		$487 Buy
+18
New +$605 ﹤0.01% 710

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Frazier Financial Advisors's RIGL Position: Q2 2026 in Review

Frazier Financial Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q2 2026, closing a stake of 18 shares — an estimated $487 sold.

Frazier Financial Advisors first reported a position in RIGL in Q1 2026 and held it in 1 quarter. The position peaked at $487 in Q1 2026. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Frazier Financial Advisors reported no remaining Rigel Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Frazier Financial Advisors sold 18 Rigel Pharmaceuticals shares in Q2 2026, an estimated $487.
  • Frazier Financial Advisors first reported a position in Rigel Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Frazier Financial Advisors's Rigel Pharmaceuticals position peaked at $487 in Q1 2026.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Frazier Financial Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.